<![CDATA[LEO Pharma A/S 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=37552>Tue, 07 Apr 2026 05:42:06 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.]]>https://www.newswire.co.kr/newsRead.php?no=1015599Fri, 25 Jul 2025 11:30:00 +0900<![CDATA[레오 파마 ‘ANZUPGO®’ 크림, 미국 FDA 승인 획득]]>https://www.newswire.co.kr/newsRead.php?no=1015600Fri, 25 Jul 2025 11:30:00 +0900<![CDATA[LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents]]>https://www.newswire.co.kr/newsRead.php?no=953923Fri, 21 Oct 2022 11:10:00 +0900<![CDATA[레오파마의 애드트랄자, EU가 중증도-중증 청소년 아토피 피부염 환자에 사용 승인]]>https://www.newswire.co.kr/newsRead.php?no=953924Fri, 21 Oct 2022 11:10:00 +0900<![CDATA[LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis]]>https://www.newswire.co.kr/newsRead.php?no=951528Mon, 19 Sep 2022 14:10:00 +0900<![CDATA[레오파마의 애드트랄자, 유럽서 중등도 이상의 청소년 AD 환자 치료제로 허가 권고]]>https://www.newswire.co.kr/newsRead.php?no=951529Mon, 19 Sep 2022 14:10:00 +0900<![CDATA[LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis]]>https://www.newswire.co.kr/newsRead.php?no=937476Fri, 31 Dec 2021 14:10:00 +0900<![CDATA[레오파마, 중증도-중증 성인 아토피 피부염 환자 위한 최초의 IL-13 표적 치료제 애드브리(트랄로키누맙) FDA 승인]]>https://www.newswire.co.kr/newsRead.php?no=937477Fri, 31 Dec 2021 14:10:00 +0900<![CDATA[LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021]]>https://www.newswire.co.kr/newsRead.php?no=922213Mon, 26 Apr 2021 10:10:00 +0900<![CDATA[LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis]]>https://www.newswire.co.kr/newsRead.php?no=922208Mon, 26 Apr 2021 09:20:00 +0900